RayKnowChina Research Map
Shortlist0

Not yet recruitingMultiple myelomaPhase 3

Registered title, quoted from ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

An open trial on multiple myeloma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06895512, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Patient must have an ECOG performance status score of 0.

    Inclusion criterion 5

  3. Patient has a history of malignancy (other than MM) within 3 years before randomization .

    Exclusion criterion 5

    Patient is known to be seropositive for history of human immunodeficiency virus (HIV) or known to have treponema pallidum antibodies (Anti-TP).

    Exclusion criterion 8

  4. A WOCBP must have a negative serum pregnancy test at screening within 72 hours prior to randomization.

    Inclusion criterion 8

    Patient is a woman who is pregnant, or breast-feeding, or planning to become pregnant or donate eggs (ova, oocytes).

    Exclusion criterion 14

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06895512, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Capable to understand and sign the ICF.
  • Patients aged ≥ 18 years .
  • Patient must have documented multiple myeloma (MM) satisfying the International Myeloma Working Group (IMWG) diagnostic criteria for MM.
  • Newly diagnosed, untreated and not considered candidate for autologous stem cell transplantation (ASCT).
  • Patient must have an ECOG performance status score of 0.
  • Patient must have pretreatment clinical laboratory values.
  • Contraceptive use by men or women should be consistent with local regulations.
  • A WOCBP must have a negative serum pregnancy test at screening within 72 hours prior to randomization.

Exclusion Criteria:

  • Patient has a diagnosis of primary amyloidosis, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), Waldenström's disease, or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.
  • Patient has plasma cell leukemia or POEMS syndrome .
  • Patient has prior or current systemic therapy or ASCT for MM before randomization.
  • Patient has peripheral neuropathy or neuropathic pain Grade 2 or higher.
  • Patient has a history of malignancy (other than MM) within 3 years before randomization .
  • Patient has clinical signs of meningeal involvement of MM.
  • Patient has known COPD, persistent asthma, or a history of asthma within the last 2 years.
  • Patient is known to be seropositive for history of human immunodeficiency virus (HIV) or known to have treponema pallidum antibodies (Anti-TP).
  • Patient is known to have active hepatitis B or C.
  • Patient has any concurrent medical or psychiatric condition or disease that is likely to interfere with the study procedures or results.
  • Patient has clinically significant cardiac disease.
  • Patient has known allergies, hypersensitivity, or intolerance to treatment drugs.
  • Patient has history of drug abuse or substance abuse.
  • Patient is a woman who is pregnant, or breast-feeding, or planning to become pregnant or donate eggs (ova, oocytes).
  • Patient had radiation therapy within 14 days of randomization.
  • Patient had plasmapheresis within 28 days of randomization.
  • Patient had major surgery within 28 days before randomization.
  • Patient in clinical trials of any other drug or device within 3 months before randomization.
  • Patient has any condition could prevent, limit, or confound the protocol-specified assessments.

Quoted from ClinicalTrials.gov, NCT06895512, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06895512, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06895512